Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Entrada Therapeutics, Inc. (TRDA : NSDQ)

• Company Description    Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON. Number of Employees: 183

• Price / Volume Information    Yesterday's Closing Price: $11.93 Daily Weekly Monthly 20 Day Moving Average: 181,022 shares Shares Outstanding: 38.28 (millions) Market Capitalization: $456.73 (millions) Beta: -0.12 52 Week High: $12.93 52 Week Low: $4.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.28% 5.20% 12 Week 15.60% 15.46% Year To Date 16.05% 15.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One Design Center Place Suite 17-500 - Boston,MA 02210 USA ph: 857-520-9158 fax: - investors@entradatx.com http://www.entradatx.com

• General Corporate Information    Officers Dipal Doshi - Chief Executive Officer Kush M. Parmar - Chairman Kory Wentworth - Chief Financial Officer Gina Chapman - Director Peter S. Kim - Director Peer Information Entrada Therapeutics, Inc. (CORR.) Entrada Therapeutics, Inc. (RSPI) Entrada Therapeutics, Inc. (CGXP) Entrada Therapeutics, Inc. (BGEN) Entrada Therapeutics, Inc. (GTBP) Entrada Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29384C108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 38.28 Most Recent Split Date: (:1) Beta: -0.12 Market Capitalization: $456.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.37 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.49 Price/Cash Flow: - Price / Sales: 17.97 EPS Growth vs. Year Ago Period: -3,233.33% vs. Previous Quarter: 11.32% Sales Growth vs. Year Ago Period: -96.53% vs. Previous Quarter: -19.52% ROE 12/31/25 - -39.83 09/30/25 - -26.42 06/30/25 - -17.81 ROA 12/31/25 - -33.32 09/30/25 - -22.08 06/30/25 - -14.55 Current Ratio 12/31/25 - 12.52 09/30/25 - 14.08 06/30/25 - 18.64 Quick Ratio 12/31/25 - 12.53 09/30/25 - 14.08 06/30/25 - 18.64 Operating Margin 12/31/25 - -565.48 09/30/25 - -168.16 06/30/25 - -92.30 Net Margin 12/31/25 - -565.48 09/30/25 - -168.16 06/30/25 - -92.30 Pre-Tax Margin 12/31/25 - -561.84 09/30/25 - -169.85 06/30/25 - -96.76 Book Value 12/31/25 - 8.01 09/30/25 - 8.96 06/30/25 - 10.00 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©